- Home
- MNDO vs GLTO Comparison
MNDO vs GLTO Comparison
Compare MNDO & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNDO
- GLTO
- Stock Information
- Founded
- MNDO 1995
- GLTO 2011
- Country
- MNDO Israel
- GLTO Denmark
- Employees
- MNDO N/A
- GLTO N/A
- Industry
- MNDO EDP Services
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- MNDO Technology
- GLTO Health Care
- Exchange
- MNDO Nasdaq
- GLTO Nasdaq
- Market Cap
- MNDO 24.4M
- GLTO 23.7M
- IPO Year
- MNDO 2000
- GLTO 2020
- Fundamental
- Price
- MNDO $1.08
- GLTO $8.34
- Analyst Decision
- MNDO
- GLTO Buy
- Analyst Count
- MNDO 0
- GLTO 1
- Target Price
- MNDO N/A
- GLTO $10.00
- AVG Volume (30 Days)
- MNDO 43.8K
- GLTO 4.8M
- Earning Date
- MNDO 11-07-2025
- GLTO 11-04-2025
- Dividend Yield
- MNDO 20.56%
- GLTO N/A
- EPS Growth
- MNDO N/A
- GLTO N/A
- EPS
- MNDO 0.15
- GLTO N/A
- Revenue
- MNDO $20,155,000.00
- GLTO N/A
- Revenue This Year
- MNDO N/A
- GLTO N/A
- Revenue Next Year
- MNDO N/A
- GLTO N/A
- P/E Ratio
- MNDO $7.13
- GLTO N/A
- Revenue Growth
- MNDO N/A
- GLTO N/A
- 52 Week Low
- MNDO $0.98
- GLTO $2.01
- 52 Week High
- MNDO $2.13
- GLTO $31.70
- Technical
- Relative Strength Index (RSI)
- MNDO 43.85
- GLTO 51.19
- Support Level
- MNDO $0.98
- GLTO $10.53
- Resistance Level
- MNDO $1.10
- GLTO $12.97
- Average True Range (ATR)
- MNDO 0.04
- GLTO 2.51
- MACD
- MNDO 0.00
- GLTO -0.47
- Stochastic Oscillator
- MNDO 62.48
- GLTO 16.73
About MNDO MIND C.T.I. Ltd.
MIND C.T.I. Ltd develops, manufactures, markets, and implements real-time and off-line convergent billing and customer care software solutions. It derives revenue from the sale of software products and services in two reportable segments, namely Billing and Related Services, which derives key revenue, and Messaging. The company has three product lines: Product Line A- billing and customer care solutions for service providers; Product Line B - call accounting and call management solutions for enterprises; and Product Line C - mobile messaging, communication, and payment solutions. Geographically, the company operates in the Americas, Europe, Asia Pacific and Africa, and Israel. It earns maximum revenue from Europe.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.